Combining neratinib with CDK4/6, mTOR and MEK inhibitors in models of HER2-positive cancer

PURPOSE: Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA-approved for HER2-overexpressing/amplified (HER2(+)) breast cancer. In this preclinical study, we explored the efficacy of neratinib in combination with inhibitors of downstream signaling in HER2(+) cancers in vitro...

全面介紹

Na minha lista:
書目詳細資料
發表在:Clin Cancer Res
Main Authors: Zhao, Ming, Scott, Stephen, Evans, Kurt W., Yuca, Erkan, Saridogan, Turcin, Zhang, Xiaofeng, Wang, Heping, Korkut, Anil, Pico, Christian X. Cruz, Demirhan, Mehmet, Kirby, Bryce, Kopetz, Scott, Diala, Irmina, Lalani, Alshad S., Piha-Paul, Sarina, Meric-Bernstam, Funda
格式: Artigo
語言:Inglês
出版: 2021
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8075007/
https://ncbi.nlm.nih.gov/pubmed/33414137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3017
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍